ABSTRACT
INTRODUCTION
In general, 9-aminoacridine derivatives work inhibiting DNA topoisomerase II (topoII). Their strong activity was due to the ability of acridine nucleus to intercalate into DNA base pair, stabilizing the DNA-topoII cleavable complex, and forming the so-called 'ternary complex' which involve DNA, intercalated compound and topoII. The poisoning of topoII activity inhibits the religation process and causes lethal double-strand breaks in DNA, leading to cell cycle arrest and apoptosis. The intercalative property was referred to the planar aromatic system of the acridine moiety. In the same context, acridines have gained strong ground for various biological activities like antimicrobial, 1 antioxidant, 2 anticancer, [3] [4] [5] antimalarial, 6 analgesic, 7 antileishmanial, 8 antinociceptive, 9 acetyl cholinesterase inhibitors 10 and antiherpes 11 etc. Amsacrine is the best known compound of 9-anilinoacridines series. It was one of the first DNA-intercalating agents to be considered as a Topoisomerase II inhibitor. The intercalation process is the strongest type of reversible binding to the double helical DNA in compounds with sufficiently large coplanar aromatic chromophore. Moreover, the cytotoxicity of most of the clinically useful DNA-intercalating agents involves the inhibition of the enzyme DNA-topoisomerase I or II. Several detailed SAR studies of acridine-based DNA-intercalating agents suggest that the mode of binding is important and the chromophore intercalate with the DNA base pairs. The chemical modification of acridines such as the introduction of different substitutions or hetero cyclic rings were allowed expansion of research on the structure activity relationship to afford new insight into molecular interactions at the receptor level. 12 In fact, it is well established that slight structural modification on 9-anilinoacridines may bring various pharmacological effects. Similarly oxazine derivatives also have various biological activities 13, 14 like antimicrobial, anticancer etc. In continuous of our previous research work, [15] [16] [17] [18] on searching new potent cytotoxic agents, we have designed 9-anilinoacridine analogues bearing the oxazine residue on anilino rings for topoisomerase II inhibition by molecular docking studies by using by using Schrodinger suit-2012 Maestro 9.3 version. The results revealed that the newly designed 9-anilinoacridine analogues derivatives exhibited good inhibition with topo II. Generally the topo II inhibitors exhibit anti tumour activity. A worthwhile approach in this area deals with the use of compounds interacting with DNA and/or inhibiting enzymes critical for cell life and replication. A good example of such a compound is amsacrine a well known antiproliferative agent used to treat some types of cancers including acute adult leukemia. 16 The crystal structure of protein Human Topoisomerase IIa (PDB ID: 1ZXM) at 1.87A o was downloaded from the Protein Data Bank (PDB) and was used in order to model the protein structure in this study. In general, the protein structures are refined for their bond orders, formal charges and missing hydrogen atoms, topologies, incomplete and terminal amide groups. The water molecules beyond 5 A o of the hetero atom were removed. The possible ionization states were generated for the heteroatom present in the protein structure and the most stable state was chosen. The hydrogen bonds were assigned and orientations of the retained water molecules were corrected. Finally, a restrained minimization of the protein structure was carried out using OPLS2005 force field to reorient side-chain hydroxyl groups and alleviate potential steric clashes. The minimization is restrained to the input protein coordinates by a predefined Root Mean Square Deviation (RMSD) tolerance of 0.3A o .
MATERIALS AND METHODS

Protein Preparation
Ligand Preparation
The structures of the ligands were generated in the CDX format using the tool Chem Draw ultra version 8.0. These ligands were then converted to the mol2 format and subjected to LigPrep module of Maestro in the Schrodinger suite 2013. They were converted from 2D to 3D structures by including stereo chemical, ionization, tautomeric variations, as well as energy minimization and optimized for their geometry, desalted and corrected for their chiralities and missing hydrogen atoms. The bonds orders of these ligands were fixed, and the charged groups were neutralized. The ionization and tautomeric states were generated between pH of 6.8 to 7.2 using Epik module. In the final stage of LigPrep, compounds were minimized using Optimized Potentials for Liquid Simulations-2005(OPLS-2005) force field in Impact package of Schrodinger until a root mean square deviation of 1.8A o was achieved. Steepest descent algorithm was used for minimization, followed by conjugate gradient method. A single low energy ring confirmation per ligand was generated and the optimized ligands were used for docking analysis.
Receptorgrid generation
The ligand ANP (phosphoaminophosphonicacid adenylate ester) was retained in the crystal structure of the prepared protein which was used for the receptor grid construction. The binding box dimensions (within which the centroid of a docked pose is confined) of the protein was set to 14A o x 14A o x 14 A o .
Validation of the docking programme
The accuracy of the docking procedure was determined by finding how closely the lowest energy pose (binding conformation) of the co-crystallized ligand predicted by the object scoring function, Glide score (G Score), resembles an experimental binding mode as determined by X-ray crystallography. Extra precision Glide docking procedure was validated by removing the co-crystallized ligand from the binding site of the protein and redocking the ligand with its binding site. The hydrogen bonding interactions and the root mean square deviation (RMSD) between the predicted conformation and the observed X-ray crystallographic conformation were used for analyzing the results.
Glide Ligand docking
The glide docking of the proposed molecules was carried out using the previously prepared receptor grid and the ligand molecules. The favourable interactions between ligand molecules and the receptor were scored using Glide ligand docking program. All the docking calculations were performed using extra precision (XP) mode and OPLS-2005 force field. The above docking process was run in a flexible docking mode which automatically generates conformations for each input ligand. The ligand poses generated were passed through a series of hierarchal filters that evaluate the ligand's interaction with the receptor. The initial filter test the spatial fit of the ligand to the defined active site, and examines the complementarity of the ligand-receptor interactions using grid-based method patterned after the empirical ChemScore function. This algorithm recognizes favourable hydrophobic, hydrogen-bonding and metal-ligation interactions, and penalizes steric clashes. Poses that pass these initial screens enter the final stage of the algorithm, which involves evaluation and minimization of a grid approximation OPLS non bonded ligand-receptor interaction energy. Finally, the minimized poses were re-scored using Glide Score scoring function. The XP-Glide score of active compounds were summarized and the fitness scores for each ligand in topo II are compared. When compared with the Glide score of standard compound containing acridine derivative ledacrine which is used as anti cancer agent, as well as potent topoisomerase, most of the proposed compounds have good Glide scores.
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The in-silico ADME properties of the proposed compounds were determined by qi prop of Schrodinger software maestro 9.3 version.
RESULTS AND DISCUSSION
The docking studies of the ligands to protein active sites were performed by an advanced molecular docking program Schrodinger Maestro-9.3 version for determining the binding affinities of the compounds. The designed analogues are docked towards the Topoisomerase-II (1ZXM) in order to ascertain their topoisomerase II inhibition activity. The compounds 1a-k ( Figure 4) showed good affinity to the receptor when compared with standard acridine derivative ledacrine. The compounds 1c, 1g and 1f have more Glide scores due to more lipophilic character and hydrogen bonding. The compounds 1c, 1g and 1f have more active due to the more lipophilic groups such as dimethoxy phenyl, 2-pyridyl and 3-pyridyl respectively. The results are summarized in the Table 1 . The best affinity modes of the docked compounds (1g, 1f) with Topoisomerase-II having good Glide score are shown in Figure 1 . The lipophilic evidence and hydrogen bonding interaction of compound 1c are shown in Figure 2 and 3 respectively. From the Figure 2 , the lipophilic evidence was clearly demonstrated. The blue colour region is the more favourable position for the substitution of lipophilic groups to increase the activity and the red colour region is non favourable position for the substitution of lipophilic groups. In the figure 3 the hydrogen bonding is formed between the ligand and the amino acid residues Table 2 .
CONCLUSION
Acridine family includes a wide range of tricyclic molecules with various biological properties. A structure-based pharmacophore model was generated and validated to obtain active topoisomerase II inhibitors from our self-compiled database of oxazine substituted 9-anilino acridine derivatives. The docking study revealed that oxazine substituted 9-anilino acridine derivatives showed better alignment at active site by interacting with all crucial amino acid residues. Thus, the in silico method adopted in the present study helped in identifying the lead compounds and also may partly explain their beneficial effect in in vivo study. On this basis, authors recently demonstrated that diverse compounds of the oxazine substituted 9-anilinoacridine series exerted Topoisomerase II inhibitor activity. Results observed in the present study clearly demonstrated that some derivatives of the oxazine substituted 9-anilinoacridine family may exert interesting antitumour activity. The compounds 1c, 1f and 1g have significant antitumour activity with therapeutic potentials and are likely to be useful as drugs after further refinement. 
